Article
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.
Clinical lung cancer - 1 Jul 2018
Wu Yi-Long, Sequist Lecia V, Tan Eng-Huat, Geater Sarayut L, Orlov Sergey, Zhang Li, Lee Ki Hyeong, Tsai Chun-Ming, Kato Terufumi, Barrios Carlos H, Schuler Martin, Hirsh Vera, Yamamoto Nobuyuki, O'Byrne Kenneth, Boyer Michael, Mok Tony, Peil Barbara, Märten Angela, Chih-Hsin Yang James, Paz-Ares Luis, Park Keunchil
Abstract excerpt
BACKGROUND: Afatinib is approved in the US, Europe, and several other regions for first-line treatment for epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Treatment-naive patients with advanced EGFRm+ NSCLC were randomized to afatinib (40 mg/d) versus cisplatin/pemetrexed (LUX-Lung 3 [LL3]) or cisplatin/gemcitabine (LUX-Lung 6 [LL6]), or versus...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.